Literature DB >> 12683839

Inhibition mode of a bisubstrate inhibitor of KDO8P synthase: a frequency-selective REDOR solid-state and solution NMR characterization.

Lilia Kaustov1, Shifi Kababya, Valery Belakhov, Timor Baasov, Yuval Shoham, Asher Schmidt.   

Abstract

In this report the mode of inhibition of mechanism-based inhibitor (2, K(i) = 0.4 microM) of 3-deoxy-d-manno-2-octulosonate-8-phosphate synthase (KDO8PS), which was designed to mimic the combined key features of its natural substrates arabinose-5-phosphate (A5P) and phoshoenolpyruvate (PEP) into a single molecule, was investigated. Our earlier solid-state NMR observations identified the inhibitor to bind in a way that partly mimics A5P, while the phosphonate moiety of its PEP-mimicking part exhibits no interactions with enzyme residues. This result was apparently in disagreement with the competitive inhibition of 2 against PEP and with the later solved crystal structure of KDO8PS-2 binary complex identifying the interactions of its PEP-mimicking part with the enzyme residues that were not detected by solid-state NMR. To solve this discrepancy, further solid-state REDOR NMR and (31)P solution NMR experiments were applied to a variety of enzyme complexes with the substrates and inhibitor. In particular, a novel frequency-selective REDOR experiment was developed and applied. Integration of the solution and solid-state NMR data clearly demonstrates that under conditions of stoichiometric enzyme-ligand ratio at thermodynamic equilibrium (a) PEP binding is unperturbed by the presence of 2 and (b) both PEP and 2 can bind simultaneously to the synthase, i.e., form a ternary complex with PEP occupying its own subsite and 2 occupying A5P's subsite. The latter observation suggests that under the conditions used in our NMR measurements, the inhibition pattern of 2 against PEP should have a mixed type character. Furthermore, the NMR data directly demonstrate the distinction between the relative binding strength of the two moieties of 2: enzyme interactions with PEP-mimicking moiety are much weaker than those with the A5P moiety. This observation is in agreement with KDO8PS-2 crystal structure showing only remote contacts of the phosphonate due to large structural changes of binding site residues. It is concluded that these phosphonate-enzyme interactions evidenced by both (31)P solution NMR and X-ray are too weak to be preserved under the lyophilization of KDO8PS-2 binary complex and therefore are not evidenced by the solid-state REDOR spectra.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12683839     DOI: 10.1021/ja028688y

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  6 in total

1.  31P-dephased, 13C-detected REDOR for NMR crystallography at natural isotopic abundance.

Authors:  Alexander I Greenwood; Mary C Clay; Chad M Rienstra
Journal:  J Magn Reson       Date:  2017-02-28       Impact factor: 2.229

2.  Frequency-selective heteronuclear dephasing and selective carbonyl labeling to deconvolute crowded spectra of membrane proteins by magic angle spinning NMR.

Authors:  Nathaniel J Traaseth; Gianluigi Veglia
Journal:  J Magn Reson       Date:  2011-03-17       Impact factor: 2.229

3.  High-resolution solid-state NMR structure of alanyl-prolyl-glycine.

Authors:  Alexander B Barnes; Loren B Andreas; Matthias Huber; Ramesh Ramachandran; Patrick C A van der Wel; Mikhail Veshtort; Robert G Griffin; Manish A Mehta
Journal:  J Magn Reson       Date:  2009-06-13       Impact factor: 2.229

4.  Frequency-selective REDOR and spin-diffusion relays in uniformly labeled whole cells.

Authors:  David M Rice; Joseph A H Romaniuk; Lynette Cegelski
Journal:  Solid State Nucl Magn Reson       Date:  2015-10-14       Impact factor: 2.293

5.  REDOR NMR characterization of DNA packaging in bacteriophage T4.

Authors:  Tsyr-Yan Yu; Jacob Schaefer
Journal:  J Mol Biol       Date:  2008-08-05       Impact factor: 5.469

Review 6.  Antibiotics and bacterial resistance in the 21st century.

Authors:  Richard J Fair; Yitzhak Tor
Journal:  Perspect Medicin Chem       Date:  2014-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.